| Name | Title | Contact Details |
|---|---|---|
Angela Drysdale |
VP, Regulatory Affairs - Infectious Disease | Profile |
Ellen Chiniara |
General Counsel | Profile |
whites shrimp dock is a Saint Helena Island, SC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
We bring many years of combined experience of equipment support, on-staff hospital imaging engineering and operations into a top-notch group of service and sales professionals. In-depth knowledge and customer focus is key. We handle all types of MRI and CT maintenance and services, including full system installation, rigging, de-installation, cold-head replacement and cryogen fills. These are just some of the reasons why leading hospitals and physician groups rely on East Coast Medical Systems to repair and service their imaging equipment.Our purpose is to express our diligence, knowledge and vigilance by pinpointing our customer`s needs and by addressing their problems, by hiring highly skilled engineers in order to provide an exact diagnosis and by being keenly watchful for any ensuing problems. To grow the organization properly, and maintain our reputation as being one of the highest regarded companies in our field, both by our customers and our peers.
House Research Insitute is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Heartbeat Perfusion Solutions is a nationwide supplier of perfusion and ECMO services that offers a consultative approach to deliver innovative Cardiovascular Perfusion and ECMO services that meet the needs of hospitals and healthcare facilities.
ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.